**Product Specification Sheet**

**Product Name:** ABBV-744  
**Catalog Number:** C2874

**Technical information:**
- **Chemical Formula:** \( \text{C}_{28}\text{H}_{30}\text{FN}_{3}\text{O}_{4} \)
- **CAS #:** 2138861-99-9
- **Molecular Weight:** 491.55
- **Purity:** > 98%
- **Appearance:** Grey solid
- **Solubility:** Soluble in DMSO up to 200 mM
- **Chemical Name:** N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide
- **Storage:** For longer shelf life, store solid powder or DMSO solution at -20°C desiccated.
- **Shelf Life:** In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition.

**Handling:**
- To make 10 mM stock solution, add 0.203mL of DMSO for each mg of ABBV-744.
- For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.

**Biological Activity:**
ABBV-744 is a selective bromodomain and extra-terminal (BET) inhibitor that preferentially bind to the 2nd bromodomains (BD) than the 1st BD pf BET family proteins (i.e., BRD2. BRD3. BRD4) [1]. This selective targeting of BD2 subsets of the BET bromodomain abolished the broad antiproliferative activities for previous generation pan BET inhibitors, and only display antiproliferative activities in a limited number of cancer cell lines, including acute myeloid leukaemia and prostate cancer that expressed the full-length androgen receptor (AR) [2]. Improved tolerability is expected due to less impact on global transcription [3].

**Reference:**

**To reorder:** [http://www.cellagentech.com/ABBV-744/](http://www.cellagentech.com/ABBV-744/)  
**For Technical Support:** [technical@cellagentech.com](mailto:technical@cellagentech.com)

*Chemicals are sold for research use only, not for clinical or diagnostic use.*